An Efficacy and Safety Study of CNTO 1275 Compared to Etanercept in Patients With Plaque Psoriasis
NCT00454584
·
clinicaltrials.gov ↗
PHASE3
Phase
COMPLETED
Status
903
Enrollment
INDUSTRY
Sponsor class
Conditions
Psoriasis
Interventions
DRUG:
CNTO 1275 45 mg
DRUG:
CNTO 1275 90 mg
DRUG:
Etanercept 50 mg
Sponsor
Centocor, Inc.